At the news
? NEUTRALIMPACT 3/10 SC 13G/A filed Nov 13, 2026 at 16:30 ET
Schonfeld Strategic Advisors LLC filed an amended Schedule 13G disclosing a passive stake of 952,959 shares (6.47%) in Inhibrx Biosciences as of September 30, 2026. This is an increase from the prior initial filing, which showed a 5%+ stake, but the exact prior share count is not provided in the current filing. The filing coincides with Inhibrx's Q3 2026 earnings release, which reported a net loss of $38.7 million and cash of $199.5 million.
- Schonfeld Strategic Advisors LLC disclosed beneficial ownership of 952,959 shares of Inhibrx common stock as of September 30, 2026.
- The stake represents 6.47% of shares outstanding, based on 14,717,660 shares outstanding as of August 7, 2026.
- This is an amendment to a prior Schedule 13G filing (initial filing on August 14, 2026).
- Schonfeld is a passive investment adviser filing under Rule 13d-1(b).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access